Evgen Pharma PLC Result of AGM (2586C)

TIDMEVG

RNS Number : 2586C

Evgen Pharma PLC

24 June 2016

 
 For immediate release    24 June 2016 
 
 

Evgen Pharma plc

Result of AGM

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, confirms that all resolutions were duly passed at its Annual General Meeting held today.

Enquiries:

 
 Evgen Pharma plc                                c/o +44 (0) 
  Dr Stephen Franklin, CEO                      20 7466 5000 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Cowles, Stephanie            +44 (0) 20 
  Watson                                           7466 5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, Margarita 
  Mitropoulou (Corporate Finance)                 +44 (0) 20 
  John Howes (Corporate Broking)                   7382 1100 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. For further information please visit www.evgen.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGEALKLADLKEFF

(END) Dow Jones Newswires

June 24, 2016 10:36 ET (14:36 GMT)